The introduction of immune checkpoint inhibitors (ICIs), including those targeting the PD-1/PD-L1 axis, has revolutionized NSCLC treatment, offering improved survival compared with traditional chemotherapy [12-14]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.